Pierre Théroux

Active 1974–2019

Also published as
Pierre Theroux
114
Papers
49,387
Citations
97
h-index
114
i10-index

Citations

Citations per year for Pierre Théroux1975: 3 citations1976: 12 citations1977: 13 citations1978: 17 citations1979: 21 citations1980: 24 citations1981: 31 citations1982: 32 citations1983: 59 citations1984: 44 citations1985: 47 citations1986: 42 citations1987: 49 citations1988: 41 citations1989: 64 citations1990: 46 citations1991: 55 citations1992: 45 citations1993: 58 citations1994: 70 citations1995: 84 citations1996: 99 citations1997: 84 citations1998: 110 citations1999: 114 citations2000: 171 citations2001: 185 citations2002: 244 citations2003: 281 citations2004: 309 citations2005: 321 citations2006: 394 citations2007: 411 citations2008: 397 citations2009: 395 citations2010: 359 citations2011: 361 citations2012: 355 citations2013: 331 citations2014: 312 citations2015: 323 citations2016: 280 citations2017: 242 citations2018: 178 citations2019: 665 citations2020: 531 citations2021: 452 citations2022: 351 citations2023: 263 citations2024: 415 citations2025: 217 citations2026: 14 citations

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 3,643 citing papers, 27.1% of this breakdownUnited Kingdom: 1,148 citing papers, 8.5% of this breakdownCanada: 786 citing papers, 5.8% of this breakdownItaly: 753 citing papers, 5.6% of this breakdownGermany: 722 citing papers, 5.4% of this breakdownChina: 555 citing papers, 4.1% of this breakdownNetherlands: 502 citing papers, 3.7% of this breakdownFrance: 486 citing papers, 3.6% of this breakdownAustralia: 438 citing papers, 3.3% of this breakdownSpain: 364 citing papers, 2.7% of this breakdownJapan: 311 citing papers, 2.3% of this breakdownSweden: 309 citing papers, 2.3% of this breakdown
0%27.1%Other 25.6%

Fields

  • Medicine85.1%
  • Biochemistry, Genetics and Molecular Biology5.6%
  • Immunology and Microbiology2.7%
  • Neuroscience1.5%
  • Engineering0.9%
  • Health Professions0.8%
  • Other3.4%

Topics

  • Acute Myocardial Infarction Research7.9%
  • Antiplatelet Therapy and Cardiovascular Diseases6.7%
  • Lipoproteins and Cardiovascular Health6.1%
  • Cardiac Imaging and Diagnostics5.5%
  • Coronary Interventions and Diagnostics4.3%
  • Diabetes, Cardiovascular Risks, and Lipoproteins2.7%
  • Other66.8%

Coauthors

All papers

Open in search
  1. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes

    Authors: , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2015 cited by 4,415

  2. Pathophysiology of Coronary Artery Disease

    Authors: , - Circulation 2005 cited by 1,986

  3. Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2015 cited by 1,970

  4. Effect of Losmapimod on Cardiovascular Outcomes in Patients Hospitalized With Acute Myocardial Infarction

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , - JAMA 2016 cited by 243

  5. Vorapaxar in the Secondary Prevention of Atherothrombotic Events

    Authors: , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2012 cited by 941

  6. Pexelizumab, an Anti-C5 Complement Antibody, as Adjunctive Therapy to Primary Percutaneous Coronary Intervention in Acute Myocardial Infarction

    Authors: , , , , , , , , , , - Circulation 2003 cited by 320

  7. Addition of Clopidogrel to Aspirin and Fibrinolytic Therapy for Myocardial Infarction with ST-Segment Elevation

    Authors: , , , , , , , , , , , - New England Journal of Medicine 2005 cited by 1,921

  8. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials

    Authors: , , , , , , , , , , , , , - The Lancet 2002 cited by 1,004

  9. Effects of Selective Matrix Metalloproteinase Inhibitor (PG-116800) to Prevent Ventricular Remodeling After Myocardial Infarction

    Authors: , , , , , , , , , , , , , - Journal of the American College of Cardiology 2006 cited by 210

  10. Comparison of Primary Percutaneous Coronary Intervention and Fibrinolytic Therapy in ST-Segment-Elevation Myocardial Infarction

    Authors: , , , , , , - Circulation 2009 cited by 181

  11. 2012 ACCF/AHA Focused Update Incorporated Into the ACCF/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction

    Authors: , , , , , , , , , , , , , , - Journal of the American College of Cardiology 2013 cited by 962

  12. The Association Between Major Depression and Levels of Soluble Intercellular Adhesion Molecule 1, Interleukin-6, and C-Reactive Protein in Patients With Recent Acute Coronary Syndromes

    Authors: , , , - American Journal of Psychiatry 2004 cited by 309

  13. Prognostic significance of blood markers of inflammation in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty and effects of pexelizumab, a C5 inhibitor: a substudy of the COMMA trial

    Authors: , , , , , , , , , , - European Heart Journal 2005 cited by 133

  14. ACC/AHA Guidelines for the Management of Patients With Unstable Angina and Non–ST-Segment Elevation Myocardial Infarction: Executive Summary and Recommendations

    Authors: , , , , , , , , , , , , , , , , , , , , , , , - Circulation 2000 cited by 4,515

  15. Cholesterol Reduction Rapidly Improves Endothelial Function After Acute Coronary Syndromes

    Authors: , , , - Circulation 1999 cited by 512

  16. Clopidogrel inhibits platelet-leukocyte interactions and thrombin receptor agonist peptide-induced platelet activation in patients with an acute coronary syndrome

    Authors: , - Journal of the American College of Cardiology 2004 cited by 177

  17. Effect of Pexelizumab, an Anti-C5 Complement Antibody, as Adjunctive Therapy to Fibrinolysis in Acute Myocardial Infarction

    Authors: , , , , , , , , , , - Circulation 2003 cited by 176

  18. ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Journal of the American College of Cardiology 2007 cited by 1,512

  19. 2012 ACCF/AHA Focused Update of the Guideline for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction (Updating the 2007 Guideline and Replacing the 2011 Focused Update)

    Authors: , , , , , , , , , , , , , , - Circulation 2012 cited by 1,095

  20. ACC/AHA guidelines for the management of patients with unstable angina and non–st-segment elevation myocardial infarction

    Authors: , , , , , , , , , , , , , , , , , , , , , , , - Journal of the American College of Cardiology 2000 cited by 970

  21. Inhibition of the Sodium-Hydrogen Exchanger With Cariporide to Prevent Myocardial Infarction in High-Risk Ischemic Situations

    Authors: , , , , , , , , , - Circulation 2000 cited by 422

  22. Depression and 1-Year Prognosis in Unstable Angina

    Authors: , , , - Archives of Internal Medicine 2000 cited by 381

  23. Impact of sodium-hydrogen exchange inhibition by cariporide on death or myocardial infarction in high-risk CABG surgery patients: results of the CABG surgery cohort of the GUARDIAN study

    Authors: , , , , , , , , , , - Journal of Thoracic and Cardiovascular Surgery 2003 cited by 112

  24. Aspirin, Heparin, or Both to Treat Acute Unstable Angina

    Authors: , , , , , , , , , , , , - New England Journal of Medicine 1988 cited by 1,280